Trial Profile
A Single Blind, Placebo Controlled, Multi-Centre Study to Investigate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of the TRPV1 Antagonist SB-705498 Against the Pain of Acute Migraine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 705498 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 12 Oct 2008 Status changed from discontinued to completed.
- 26 Nov 2006 New trial record.